• Register
  • Login

European Journal of Molecular & Clinical Medicine

  • Home
  • Browse
    • Current Issue
    • By Issue
    • By Subject
    • Keyword Index
    • Author Index
    • Indexing Databases XML
  • Journal Info
    • About Journal
    • Aims and Scope
    • Editorial Board
    • Publication Ethics
    • Indexing and Abstracting
    • Peer Review Process
    • News
  • Guide for Authors
  • Submit Manuscript
  • Contact Us
Advanced Search

Notice

As part of Open Journals’ initiatives, we create website for scholarly open access journals. If you are responsible for this journal and would like to know more about how to use the editorial system, please visit our website at https://ejournalplus.com or
send us an email to info@ejournalplus.com

We will contact you soon

  1. Home
  2. Volume 9, Issue 2
  3. Author

Online ISSN: 2515-8260

Volume9, Issue2

Efficacy of bepotastine besilate ophthalmic solution 1.5% for seasonal allergic conjunctivitis: A randomized/placebocontrolled/ natural exposure/clinical trial

    Dr. Kedar Nemivant, Dr. Shaikh Najamoddin Aleemoddin

European Journal of Molecular & Clinical Medicine, 2022, Volume 9, Issue 2, Pages 2332-2341

  • Show Article
  • Download
  • Cite
  • Statistics
  • Share

Abstract

Allergic conjunctivitis (AC) affects an estimated 20% of the population in the Western world,
with a large fraction suffering due to seasonal or perennial allergen exposures. Bepotastine
besilate ophthalmic solution (BBOS) 1.5%, a dual-acting histamine (H,) receptor antagonist
and mast cell stabilizer, is indicated for itching associated with AC. This study was designed
to evaluate the efficacy and safety of BBOS 1.5% for reducing ocular itching associated with
AC in subjects enrolled in a natural exposure trial. Eligible subjects in a multicenter, doublemasked,
randomized, parallel-group, placebo-controlled, natural exposure clinical trial were
randomly assigned to either BBOS 1,5% or placebo eyedrops on a 1:1 basis and instilled 1
drop of the test agent into both eyes twice daily for 2 weeks. The mean change from baseline
in instantaneous and reflective ocular itching scores at the end of 2 weeks of treatment were
evaluated based on subject-assessed severity of instantaneous and reflective itching. Subjectreported
adverse events (AEs) were also recorded for safety. Treatment with BBOS 1.5%
significantly reduced instantaneous and reflective ocular itching scores from baseline
compared with placebo over the 2-week study period (p = 0.007 and p = 0.005, respectively).
BBOS 1.5% was well tolerated, and AEs were generally transient and mild. This clinical
study indicates BBOS 1.5% effectively and safely treated ocular itching in a natural exposure
allergy study and is a useful treatment option for the management of ocular itching associated
with AC. (ClinicalTrials.gov identifier number: NCT01174823).
Keywords:
  • PDF (412 K)
  • XML
(2022). Efficacy of bepotastine besilate ophthalmic solution 1.5% for seasonal allergic conjunctivitis: A randomized/placebocontrolled/ natural exposure/clinical trial. European Journal of Molecular & Clinical Medicine, 9(2), 2332-2341.
Dr. Kedar Nemivant, Dr. Shaikh Najamoddin Aleemoddin. "Efficacy of bepotastine besilate ophthalmic solution 1.5% for seasonal allergic conjunctivitis: A randomized/placebocontrolled/ natural exposure/clinical trial". European Journal of Molecular & Clinical Medicine, 9, 2, 2022, 2332-2341.
(2022). 'Efficacy of bepotastine besilate ophthalmic solution 1.5% for seasonal allergic conjunctivitis: A randomized/placebocontrolled/ natural exposure/clinical trial', European Journal of Molecular & Clinical Medicine, 9(2), pp. 2332-2341.
Efficacy of bepotastine besilate ophthalmic solution 1.5% for seasonal allergic conjunctivitis: A randomized/placebocontrolled/ natural exposure/clinical trial. European Journal of Molecular & Clinical Medicine, 2022; 9(2): 2332-2341.
  • RIS
  • EndNote
  • BibTeX
  • APA
  • MLA
  • Harvard
  • Vancouver
  • Article View: 26
  • PDF Download: 99
  • LinkedIn
  • Twitter
  • Facebook
  • Google
  • Telegram
Journal Information

Publisher:

Email:  editor.ejmcm21@gmail.com

  • Home
  • Glossary
  • News
  • Aims and Scope
  • Privacy Policy
  • Sitemap

 

For Special Issue Proposal : editor.ejmcm21@gmail.com

This journal is licensed under a Creative Commons Attribution 4.0 International (CC-BY 4.0)

Powered by eJournalPlus